Browse Studies — Arctuva

Phase 1

Phase Ib Study to Assess the Efficacy and Safety of Epcoritamab in Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder

This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has co…

Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative DisorderEBV-Related Post-Transplant Lymphoproliferative DisorderRecurrent Monomorphic Post-Transplant Lymphoproliferative Disorder+3 more

Estimated

~$10 – $7,500

Timothy VoorheesNCT06672705

Phase 2

A Phase II Study of Combination Epcoritamab-Lenalidomide in Patients With Refractory/Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

This phase II trial tests how well the combination of epcoritamab and lenalidomide work in treating patients with immunodeficiency-related large B-cell lymphom…

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Polymorphic Post-Transplant Lymphoproliferative DisorderRefractory B-Cell Non-Hodgkin Lymphoma

Estimated

~$10 – $7,500

Reem KarmaliNCT06723457

Phase 2

Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

This phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder. Post-…

Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative Disorder

Estimated

~$10 – $7,500

Timothy VoorheesNCT05786040